Notably, FABP4 is a reported target of VEGF/VEGFR2 axis [64], has been implicated in angiogenesis associated with glioblastoma aggressiveness [65], and its deficiency in mice has inhibitory effects on ovarian tumor vasculature [25]. Here, FABP4 is linked to ovarian neoplasm.